[go: up one dir, main page]

US20010023294A1 - New process for the preparation of isoindoline - Google Patents

New process for the preparation of isoindoline Download PDF

Info

Publication number
US20010023294A1
US20010023294A1 US09/785,956 US78595601A US2001023294A1 US 20010023294 A1 US20010023294 A1 US 20010023294A1 US 78595601 A US78595601 A US 78595601A US 2001023294 A1 US2001023294 A1 US 2001023294A1
Authority
US
United States
Prior art keywords
isoindoline
process according
tetrahydrofuran
preparation
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/785,956
Other versions
US6320058B2 (en
Inventor
Jean-Claude Souvie
Claude Fugier
Jean-Pierre Lecouve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Assigned to ADIR ET COMPAGNIE reassignment ADIR ET COMPAGNIE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FUGIER, CLAUDE, LECOUVE, JEAN-PIERRE, SOUVIE, JEAN-CLAUDE
Publication of US20010023294A1 publication Critical patent/US20010023294A1/en
Application granted granted Critical
Publication of US6320058B2 publication Critical patent/US6320058B2/en
Assigned to LES LABORATOIRES SERVIER reassignment LES LABORATOIRES SERVIER MERGER (SEE DOCUMENT FOR DETAILS). Assignors: ADIR ET COMPAGNIE
Assigned to KISSEI PHARMACEUTICAL COMPANY LTD reassignment KISSEI PHARMACEUTICAL COMPANY LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LES LABORATOIRES SERVIER
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Definitions

  • Isoindoline is a synthesis intermediate that is widely used, especially in the preparation of pharmaceutical active ingredients.
  • isoindoline is an important intermediate in the synthesis of 2-(S)-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)butyric acid of formula (I):
  • the compound of formula (I), and its addition salts and hydrates have especially valuable pharmacological properties. They are very powerful insulin secretors, which makes them useful in the treatment of non-insulin-dependent diabetes.
  • the compound of formula (I), its preparation and its therapeutic use have been described in Patent Specification EP 0 507 534. Its industrial preparation is described in Patent Specification WO 99/01430. Given the pharmaceutical value of this compound, it was important to be able to obtain the intermediate isoindoline using a high-performance industrial synthesis process.
  • Patent Specifications FR 1 577 845 and FR 1 578 582 describe the preparation of isoindoline by reacting ⁇ , ⁇ ′-dichlorobenzene with hexamethylenetetraamine, followed by treatment of the resulting ammonium salt in an HCl or SO 2 medium, and then cyclisation of the resulting o-chloromethyl-benzylamine compound in a basic medium. That method is especially lengthy and does not enable isoindoline to be obtained with a satisfactory yield.
  • That process has several disadvantages. It has not been possible to reproduce the stated yields (91 to 98%). After removal of the catalyst by filtration and removal of the solvent by distillation, it has not been possible to distill off any compound from the medium heated to 120° C. in vacuo at 20 mbars. Moreover, in the case of industrial-scale processing the presence of ammonia in the reaction mixture requires a special installation in order to protect the environment.
  • isoindoline as an intermediate in the synthesis of pharmaceutical active ingredients, especially 2-(S)-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)-butyric acid, and given the absence of a process that enables it to be obtained with a good yield and satisfactory purity, starting from inexpensive starting materials but avoiding the use of ammonia, the Applicant carried out in-depth research, which resulted in the development of a new process for the preparation of isoindoline.
  • This process enables isoindoline to be obtained in a single step, by simple catalytic hydrogenation of phthalonitrile, a commercial product, without the addition of ammonia, with a yield of more than 75% and with very good purity.
  • the catalyst used is 5% Pt/C.
  • Pt/C enabled isoindoline to be obtained within a reasonable reaction time
  • the amount of Pt/C used is from 10 to 25%, preferably 20%, of the weight of the phthalonitrile.
  • the solvent used is tetrahydrofuran, a mixture of tetrahydrofuran/-water in which the water content is less than 10%, preferably less than 5%, or dimethoxyethane.
  • tetrahydrofuran used on its own or in the presence of a limited amount of water
  • dimethoxyethane enabled a satisfactory conversion rate to be obtained (Table 2).
  • the hydrogen pressure inside the reactor is from 100 to 180 bars and preferably from 150 to 180 bars.
  • the temperature of the reaction mixture is from 30 to 100° C. and preferably from 50 to 70° C.
  • the isoindoline obtained under those conditions can then readily be isolated from its reaction medium by distillation, and then purified by precipitation in the form of a hydrochloride from a solvent, such as, for example, ethanol or ethyl acetate.
  • a solvent such as, for example, ethanol or ethyl acetate.
  • the isoindoline hydrochloride so obtained has very good purity and contains, for example, less than 1.5%, preferably less than 0.2%, of 2-methylbenzylamine, which makes its use especially advantageous in the synthesis of active ingredients, such as the compound of formula (I).
  • the purity of the compounds was determined by gas-phase chromatography over an OPTIMA-5 amine column (Macherey-Nagel), using FID detection (flame ionisation) at 280° C.
  • the reaction was carried out in an autoclave. 20 g of 5% platinum on carbon are added to 100 g of phthalonitrile dissolved in tetrahydrofuran. After purging with nitrogen, the mixture is heated at 60° C. and a hydrogen pressure of 180 bars is applied for 5 to 6 hours. After decompression and purging with nitrogen, the catalyst is removed by filtration. The tetrahydrofuran is distilled off from the filtrate at atmospheric pressure, and then isoindoline is in turn distilled off from the residue under a vacuum of 23 mbars. at a temperature of 100° C.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Process for the industrial synthesis of isoindoline by catalytic hydrogenation of phthalonitrile.
Application in the synthesis of 2-(S)-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)-butyric acid, its pharmaceutically acceptable salts and its hydrates.

Description

    BACKGROUND OF THE INVENTION
  • Isoindoline is a synthesis intermediate that is widely used, especially in the preparation of pharmaceutical active ingredients. [0001]
  • In particular, isoindoline is an important intermediate in the synthesis of 2-(S)-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)butyric acid of formula (I): [0002]
    Figure US20010023294A1-20010920-C00001
  • its pharmaceutically acceptable salts and its hydrates. [0003]
  • The compound of formula (I), and its addition salts and hydrates, have especially valuable pharmacological properties. They are very powerful insulin secretors, which makes them useful in the treatment of non-insulin-dependent diabetes. The compound of formula (I), its preparation and its therapeutic use have been described in Patent Specification EP 0 507 534. Its industrial preparation is described in Patent Specification WO 99/01430. Given the pharmaceutical value of this compound, it was important to be able to obtain the intermediate isoindoline using a high-performance industrial synthesis process. [0004]
  • DESCRIPTION OF THE PRIOR ART
  • A number of methods for the preparation of isoindoline are already known. No process described in the literature, however, enables isoindoline to be obtained with satisfactory purity and yield, whilst still being readily transposable to an industrial scale and advantageous from the point of view of profitability. [0005]
  • The preparation of isoindoline by the electrolytic or chemical reduction of phthalimide is described in the journals Bull. Soc. Chim. France 1956, 906-910, J. Pharm. Sci. 1964, 53 (8), 981 and J. Org. Chem. 1988, 53 (22), 5381-5383. [0006]
  • Those processes do not, however, enable isoindoline to be obtained in a yield of more than 50%. [0007]
  • The preparation of isoindoline by cyclising α,α′-dibromo-xylene in the presence of p-toluenesulphonylamine, followed by deprotection of the resulting N-(p-toluenesulphonyl)-isoindoline is described in the journals J. Org. Chem. 1957, 22, 1255-6 and Org. Synth. Collect. Vol. V, 406-408 and 1064-[0008] 1066. That method, in addition to its low yield (less than 50%), has the disadvantage of using a highly lacrimogenic starting material.
  • Patent Specifications FR 1 577 845 and FR 1 578 582 describe the preparation of isoindoline by reacting α,α′-dichlorobenzene with hexamethylenetetraamine, followed by treatment of the resulting ammonium salt in an HCl or SO[0009] 2 medium, and then cyclisation of the resulting o-chloromethyl-benzylamine compound in a basic medium. That method is especially lengthy and does not enable isoindoline to be obtained with a satisfactory yield.
  • The journal Izvestia Eng. Ed. 1959, 1778-80, describes the synthesis of isoindoline by hydrogenation of phthalonitrile at 100-120 atm in a dioxane/ammonia mixture, in the presence of nickel or cobalt at 100° C. [0010]
  • That process has several disadvantages. It has not been possible to reproduce the stated yields (91 to 98%). After removal of the catalyst by filtration and removal of the solvent by distillation, it has not been possible to distill off any compound from the medium heated to 120° C. in vacuo at 20 mbars. Moreover, in the case of industrial-scale processing the presence of ammonia in the reaction mixture requires a special installation in order to protect the environment. [0011]
  • DETAILED DESCRIPTION OF THE INVENTION
  • Given the value of isoindoline as an intermediate in the synthesis of pharmaceutical active ingredients, especially 2-(S)-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)-butyric acid, and given the absence of a process that enables it to be obtained with a good yield and satisfactory purity, starting from inexpensive starting materials but avoiding the use of ammonia, the Applicant carried out in-depth research, which resulted in the development of a new process for the preparation of isoindoline. [0012]
  • This process enables isoindoline to be obtained in a single step, by simple catalytic hydrogenation of phthalonitrile, a commercial product, without the addition of ammonia, with a yield of more than 75% and with very good purity. [0013]
  • In order to obtain that result, the following operating conditions must be applied: [0014]
  • The catalyst used is 5% Pt/C. In fact, it became apparent, surprisingly, that of all the catalysts generally employed, only Pt/C enabled isoindoline to be obtained within a reasonable reaction time (Table 1). [0015]
  • The amount of Pt/C used is from 10 to 25%, preferably 20%, of the weight of the phthalonitrile. [0016]  
    TABLE 1
    Catalyst Hydrogenation time % isoindoline
    Pd/C 20 h 1
    Raney Ni 20 h 0
    Rh/C 20 h 0
    Ru/C 20 h 0
    Pt/C  6 h 89.9
  • Reaction conditions: tetrahydrofuran, 20% by weight of catalyst, 60° C., 180 bars of hydrogen [0017]
  • The solvent used is tetrahydrofuran, a mixture of tetrahydrofuran/-water in which the water content is less than 10%, preferably less than 5%, or dimethoxyethane. In fact, it became apparent, surprisingly, that only tetrahydrofuran (used on its own or in the presence of a limited amount of water) and dimethoxyethane enabled a satisfactory conversion rate to be obtained (Table 2). [0018]
    TABLE 2
    Solvent Hydrogenation time % isoindoline
    tetrahydrofuran  6 h 89.9
    tetrahydrofuran/water 98/2  6 h 89.3
    dimethoxyethane  9 h 86.2
    dioxane 20 h 40
    ethanol 20 h 49
    dimethylformamide 20 h 0
  • Reaction conditions: catalyst Pt/C (20% by weight), 60° C., 180 bars of hydrogen [0019]
  • The hydrogen pressure inside the reactor is from 100 to 180 bars and preferably from 150 to 180 bars. [0020]
  • The temperature of the reaction mixture is from 30 to 100° C. and preferably from 50 to 70° C. [0021]
  • The isoindoline obtained under those conditions can then readily be isolated from its reaction medium by distillation, and then purified by precipitation in the form of a hydrochloride from a solvent, such as, for example, ethanol or ethyl acetate. [0022]
  • The isoindoline hydrochloride so obtained has very good purity and contains, for example, less than 1.5%, preferably less than 0.2%, of 2-methylbenzylamine, which makes its use especially advantageous in the synthesis of active ingredients, such as the compound of formula (I). [0023]
  • By way of illustration, enantioselective reduction by catalytic hydrogenation of the isoindoline obtained according to the process of the invention enables cis-perhydroisoindole to be obtained with highly satisfactory purity and yield. That compound, when reacted with the anhydride of formula (II): [0024]
    Figure US20010023294A1-20010920-C00002
  • yields the compound of formula (III): [0025]
    Figure US20010023294A1-20010920-C00003
  • the catalytic hydrogenation of which in the presence of an asymmetric catalyst yields the compound of formula (I). [0026]
  • The following Examples illustrate the invention but do not limit it in any way. [0027]
  • The purity of the compounds was determined by gas-phase chromatography over an OPTIMA-5 amine column (Macherey-Nagel), using FID detection (flame ionisation) at 280° C.[0028]
  • EXAMPLE 1
  • Isoindoline [0029]
  • The reaction was carried out in an autoclave. 20 g of 5% platinum on carbon are added to 100 g of phthalonitrile dissolved in tetrahydrofuran. After purging with nitrogen, the mixture is heated at 60° C. and a hydrogen pressure of 180 bars is applied for 5 to 6 hours. After decompression and purging with nitrogen, the catalyst is removed by filtration. The tetrahydrofuran is distilled off from the filtrate at atmospheric pressure, and then isoindoline is in turn distilled off from the residue under a vacuum of 23 mbars. at a temperature of 100° C. [0030]
  • Isoindoline is thus obtained with a yield of 75% and purity of 89%. [0031]
  • EXAMPLE 2
  • Isoindoline Hydrochloride [0032]
  • A solution of 2.5N hydrochloric acid in ethyl acetate is added to 69 g of isoindoline obtained in Example 1 dissolved in 458 ml of ethyl acetate. The resulting solid is recovered by filtration, washed with ethyl acetate and then dried in an oven. Isoindoline hydrochloride is thus obtained with a yield of 82% and a purity of 98.5% with less than 1.5% of 2-methylbenzylamine. [0033]

Claims (12)

We claim:
1. A process for the synthesis of isoindoline, wherein a solution of phthalonitrile in tetrahydrofuran, in a mixture of tetrahydrofuran/water, or in dimethoxyethane is subjected to a hydrogen pressure of from 100 to 180 bars, at a temperature of from 30 to 100° C., and in the presence of 5% Pt/C.
2. A process according to
claim 1
, wherein the solvent is tetrahydrofuran.
3. A process according to
claim 1
, wherein the solvent is a mixture of tetrahydrofuran/water in which the water content does not exceed 10%.
4. A process according to
claim 3
, wherein the solvent is a mixture of tetrahydrofuran/water in which the water content does not exceed 5%.
5. A process according to
claim 1
, wherein the solvent is dimethoxyethane.
6. A process according to
claim 1
, wherein the hydrogen pressure is from 150 to 180 bars.
7. A process according to
claim 1
, wherein the temperature is from 50 to 70° C.
8. A process according to
claim 1
, wherein the amount of Pt/C used is from 10 to 25% of the weight of phthalonitrile employed.
9. A process according to
claim 8
, wherein the amount of Pt/C used is 20% of the weight of phthalonitrile employed.
10. A process according to
claim 1
, wherein the amount of 2-methylbenzylamine in the isoindoline obtained does not exceed 1.5%.
11. A process according to
claim 10
, wherein the amount of 2-methylbenzylamine in the isoindoline obtained does not exceed 0.2%.
12. Use of the isoindoline obtained according to any one of
claims 1
to
11
for the synthesis of 2-(S)-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)-butyric acid, its pharmaceutically acceptable salts and its hydrates.
US09/785,956 2000-02-25 2001-02-16 Process for the preparation of isoindoline Expired - Fee Related US6320058B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0002383A FR2805535B1 (en) 2000-02-25 2000-02-25 NEW PROCESS FOR THE PREPARATION OF ISOINDOLINE
FR0002383 2000-02-25

Publications (2)

Publication Number Publication Date
US20010023294A1 true US20010023294A1 (en) 2001-09-20
US6320058B2 US6320058B2 (en) 2001-11-20

Family

ID=8847398

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/785,956 Expired - Fee Related US6320058B2 (en) 2000-02-25 2001-02-16 Process for the preparation of isoindoline

Country Status (23)

Country Link
US (1) US6320058B2 (en)
EP (1) EP1127876B1 (en)
JP (1) JP3545351B2 (en)
KR (1) KR100464183B1 (en)
CN (1) CN1197848C (en)
AR (1) AR027537A1 (en)
AT (1) ATE227707T1 (en)
AU (1) AU774807B2 (en)
BR (1) BR0100757A (en)
CA (1) CA2338899C (en)
DE (1) DE60100044T2 (en)
DK (1) DK1127876T3 (en)
EA (1) EA003515B1 (en)
ES (1) ES2187492T3 (en)
FR (1) FR2805535B1 (en)
HK (1) HK1040248B (en)
HU (1) HUP0100881A3 (en)
NO (1) NO318881B1 (en)
NZ (1) NZ510205A (en)
PL (1) PL346035A1 (en)
PT (1) PT1127876E (en)
SI (1) SI1127876T1 (en)
ZA (1) ZA200101529B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126930B2 (en) 2012-01-06 2015-09-08 Lonza Ltd. Method for preparation of octahydrocyclopenta[c]pyrrole

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070062520A (en) * 2004-08-16 2007-06-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Method for preparing isoindole derivatives
CN1324010C (en) * 2005-01-12 2007-07-04 江苏省药物研究所 Preparation of miglitol
CN100441570C (en) * 2006-05-24 2008-12-10 严洁 A kind of preparation and quality control method of mitiglinide calcium
FR2967673B1 (en) * 2010-11-24 2012-12-28 Minakem SYNTHESIS OF N-HETEROCYCLES BY REDUCTIVE ALKYLATION OF CYAN DERIVATIVES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2773902A (en) * 1954-05-10 1956-12-11 California Research Corp Hydrogenation of phthalonitriles
US4254059A (en) * 1979-08-01 1981-03-03 Allied Chemical Corporation Process for hydrogenation of nitriles

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126930B2 (en) 2012-01-06 2015-09-08 Lonza Ltd. Method for preparation of octahydrocyclopenta[c]pyrrole

Also Published As

Publication number Publication date
ATE227707T1 (en) 2002-11-15
NO20010936L (en) 2001-08-27
JP3545351B2 (en) 2004-07-21
DE60100044D1 (en) 2002-12-19
EP1127876B1 (en) 2002-11-13
AU2323701A (en) 2001-08-30
HUP0100881A2 (en) 2002-02-28
HU0100881D0 (en) 2001-04-28
HUP0100881A3 (en) 2002-12-28
FR2805535A1 (en) 2001-08-31
DK1127876T3 (en) 2002-12-23
EA200100179A2 (en) 2001-08-27
SI1127876T1 (en) 2003-02-28
EA200100179A3 (en) 2001-12-24
US6320058B2 (en) 2001-11-20
ES2187492T3 (en) 2003-06-16
DE60100044T2 (en) 2003-07-24
BR0100757A (en) 2001-09-25
CA2338899A1 (en) 2001-08-25
HK1040248B (en) 2005-12-02
FR2805535B1 (en) 2002-04-12
AU774807B2 (en) 2004-07-08
ZA200101529B (en) 2001-08-29
HK1040248A1 (en) 2002-05-31
CN1197848C (en) 2005-04-20
NO20010936D0 (en) 2001-02-23
CN1320595A (en) 2001-11-07
EP1127876A1 (en) 2001-08-29
CA2338899C (en) 2007-07-24
PT1127876E (en) 2003-03-31
KR100464183B1 (en) 2004-12-31
EA003515B1 (en) 2003-06-26
PL346035A1 (en) 2001-08-27
JP2001261643A (en) 2001-09-26
NO318881B1 (en) 2005-05-18
AR027537A1 (en) 2003-04-02
NZ510205A (en) 2002-11-26
KR20010085534A (en) 2001-09-07

Similar Documents

Publication Publication Date Title
JP2002507222A (en) Method for producing substituted perhydroisoindole
KR100704590B1 (en) Novel Process for Making (+)-cis-sertraline
HU227474B1 (en) Process for industrial scale production of high purity donepezil hydrochloride polymorph i.
US6320058B2 (en) Process for the preparation of isoindoline
RU2181358C2 (en) Method of synthesis of sertraline from chiral tetralone
EA007743B1 (en) Process for synthesizing derivatives of 1,3,4,6-tetrahydro-2h-3-benzazepin-2-one
US7795438B2 (en) Processes for producing 1-benzyl-4-[(5,6-dimethoxy-1indanon)-2-yl]methylpiperidine and hydrochloride
JP2646907B2 (en) Method for producing 6-amino-7-fluoro-2H-1,4-benzoxazin-3 (4H) -one
US20080275252A1 (en) Atipamezole Hydrochloride Crystallization Method
MXPA01001921A (en) New process for the preparation of isoindoline
US5571928A (en) 4-amino-3-hydroxy-phthalimidine, and a process for the preparation thereof
US4910343A (en) Nitroamines
US20040077550A1 (en) Process for preparing distamycin derivatives
EP1899310B1 (en) Stereoselective hydrogenation process for preparing cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-methoxy-5,6,7,8-tetrahydronaphthalene hydrochloride
EP0056343B1 (en) Process for the preparation of 4-aminobutyramide
US5284960A (en) Process for the production of 5-chloroxindole
JP2795492B2 (en) Method for producing indole or indole derivative
EP0330186A2 (en) 2-(1-alkylaminoalkyl)-3-hydroxy-1,4-naphthoquinone, process for its production and processes for producing 2-(1-alkenyl)-3-hydroxy-1,4-naphthoquinone and 2-alkyl-3-acyloxy-1,4-naphthoquinone by using it
CN117567260A (en) A kind of synthesis method of hydroxyquinone
JP2996713B2 (en) Process for producing 2,3-cyclohexenopyridine
CN114105961A (en) Preparation method of IDO1 inhibitor (LY-3381916)
JP3267025B2 (en) Method for producing N- (6-chloro-3-pyridylmethyl) -N-alkylamine
GB2202535A (en) Process for the preparation of alpha -amino-and alpha -azido-n-acyl-2, 6- dimethylanilines
CA2448300A1 (en) Process for preparing sertraline intermediates

Legal Events

Date Code Title Description
AS Assignment

Owner name: ADIR ET COMPAGNIE, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOUVIE, JEAN-CLAUDE;FUGIER, CLAUDE;LECOUVE, JEAN-PIERRE;REEL/FRAME:011718/0977

Effective date: 20010125

AS Assignment

Owner name: LES LABORATOIRES SERVIER, FRANCE

Free format text: MERGER;ASSIGNOR:ADIR ET COMPAGNIE;REEL/FRAME:012475/0568

Effective date: 20010730

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: KISSEI PHARMACEUTICAL COMPANY LTD, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LES LABORATOIRES SERVIER;REEL/FRAME:018420/0334

Effective date: 20060310

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20131120